Index

Page numbers in italics refer to illustrations; those in bold refer to tables

abatacept 154
accommodation 161
activation-induced cell death (AICD) 120, 121
adaptive immunity 143, 144
age-related changes in immune responses 281–283, 282
alemtuzumab 156–157, 194, 203
adverse effects 203
efficacy 203
AlloMap® 264
anemia 255–256
animal models 316–336
B cell mediated injury 333
composite tissue allotransplantation 331
humanized mice 334–336
ischemia reperfusion injury 330
large animal transplant models 326–330
heart transplantation 329
intestinal transplantation 329–330
islet and pancreas transplantation 327–329
kidney transplantation 327, 328
MHC typing 334, 335
need for 317
rejection 330–331
small animal transplant models 321–326, 321–322
heart transplantation 322–323, 323
intestinal transplantation 324, 325
islet and pancreas transplantation 325
kidney transplantation 323–324, 324
liver and hepatocyte transplantation 325–326, 326
lung and trachea transplantation 324–325
skin transplantation 321–322
small versus large animal models 317–319
tolerance 331–333
antibody-mediated rejection (ABMR) 143, 145–146, 145, 184
animal models 333
inhibition of 212–213
kidney transplant 146, 224
lung transplant 231
management 207–211, 208
pathogenesis 186
xenografts 290–291
anti-endothelial cell antibodies (AECAs) 100
antigen presentation 28–29, 29
direct presentation 36, 90–91, 174
HLA function 90
indirect presentation 35–36, 91, 174
in transplantation 35–36, 36
pathways 174–175
cross-presentation pathway 28–29
MHC class I pathway 28, 174–175
MHC class II pathway 28, 174–175
semidirect presentation 36, 91
antigen-presenting cells 28, 29, 35–36, 104
graft-versus-host disease sensors 173–176
functional modulation 175–177
lymph nodes 11
anti-HLA antibodies 94–99
crossmatch testing 94–95, 97
virtual crossmatch 96–97, 99
detection and characterization 96–97, 98
sensitization assessment 98–99
see also human leukocyte antigens (HLAs)
anti-MICA antibodies 100

Transplant Immunology, First Edition. Edited by Xian Chang Li and Anthony M. Jevnikar.
© 2016 John Wiley & Sons, Ltd. Published 2016 by John Wiley & Sons, Ltd.
Copyright © American Society of Transplantation 2016.
Companion website: www.wiley.com/go/li/transplantimmunology
antithymocyte globulin (ATG) 156–157, 193, 202–203
apoptosis 119–122, 120
role in allograft tolerance 122
apoptosome 121
artificial kidneys 292, 292
atacicept (TACI-Ig) 44, 148
autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APEDEC) 9
autoimmune regulator (AIRE) gene 9
avascular necrosis 254
azathioprine 190, 196–197
adverse effects 196–197
mechanism of action 196
bacteriuria 239
basiliximab 193, 203–204
adverse effects 204
efficacy 204
mechanism of action 203
B cell activating factor (BAF) 211
B cell-directed therapies 211
B cells 26, 40–44
activation 13, 21–22, 42, 42, 42
age-related changes 283
development 4, 40–41, 41
function 41–42
lymph nodes 12–14
memory B cell generation 146, 146
operational tolerance signatures 269–271
preemptive B cell depletion 44
role in transplantation 42–43, 43
spleen 15
marginal zone 15–16, 41
subsets 41–42
tolerance mechanisms 150, 151
Bcl-2 protein family 119–121, 120
belatacept 114, 154, 194, 204
adverse effects 204
development of 319
efficacy 204
elderly patients 289
mechanism of action 204
belimumab 44, 211
biomarkers 260–278, 265, 277
metabolomics 276
need for 260–261
next-generation sequencing 273–276
outlook 277–278
rejection 148, 262–268
microRNA 265–266, 267
mRNA profiling 260, 261, 262–264, 263
proteomics 266–268
tolerance 159, 268–273, 274
B cell signatures 269–271
T cell signatures 271–272
bisphosphonates 254
BK (polyoma) virus infection 242–243
bone marrow 3–7
cell trafficking 6
function 3–5
role in rejection and tolerance 6–7
simultaneous bone marrow and organ transplantation 6
structure 3, 4
very small embryonic-like stem cells (VSELs) 300
bone mineral disorder 253–255
risk factors 253
bortezomib 44, 148–149, 208, 210
brain, stem cell-based therapy 301
bronchiolitis obliterans syndrome (BOS) 231
bronchus-associated lymphoid tissues (BALTs) 19
inducible (iBALTs) 22
calcineurin inhibitors (CNIs) 108–109, 147, 187, 197–199
adverse effects 197–198
choice of 199
drug interactions 198
efficacy 197
hematopoietic cell transplantation 168
kidney transplantation 220
liver transplantation 227
mechanism of action 197, 198
minimization strategy 206–207
CNI avoidance 207
CNI reduction 206–207
CNI substitution/withdrawal 207
canine models see animal models
cardiac allograft vasculopathy (CAV) 33, 233
caspase activation 120, 121
graft-versus-host disease relationship 171
CCL21 9, 13–14
CCR7 13–14
CD28 113–114
CD28-B7 costimulation pathway 153, 154
CD34 14
CD40 115, 131
  CD40-CD40L costimulatory pathway 153–154
CD80 113–115
CD86 113–115
CD154 115
cell trafficking 179–180
  bone marrow 6
  graft-versus-host disease 179–180
  lymph nodes 13–14
  spleen 17
  thymus 9–10
cellular and functional MRI (CMRI) 308
Cinacalet 254, 255
CN inhibitors see calcineurin inhibitors (CNIs)
common lymphoid progenitors (CLPs) 26
common myeloid progenitors (CMPs) 26
complement fixation 146
complications see transplant-related complications
composite tissue allotransplantation (CTA) 331
costimulation
  blockade 147, 153–154, 153
  resistance 156
  graft-versus-host disease 175, 176
costimulatory molecules 112–115, 114, 153
creatinine 260
crossmatch testing 94–95, 97
  positive crossmatch patient management 208, 211–213
  virtual crossmatch 96–97, 99
cryptopatches 18
CTLA-4 113–114, 114, 154
CXCL12 6, 9–10
CXCL13 14
CXCR4 6
CXCR5 14
cyclosporine 30, 109, 157, 188, 197–199
  adverse effects 197–198
  hypertension 255
  drug interactions 198
  efficacy 197
  hematopoietic cell transplantation 168
  mechanism of action 197, 198
cytokines 49–64, 115
  acute phase 49–54
  adaptive immunity 59–61
  common γ, family 54–57, 54
gene therapy 314
graft-versus-host disease relationships 171, 179
IL-12 family 57–59
immunoregulatory 61–64
signaling pathways 50, 115–117, 116
withdrawal 119–121
see also specific cytokines
cytomegalovirus (CMV) infection 239–241, 240
diagnosis 240
prophylaxis 241, 256
treatment 241
damage-associated molecular pattern (DAMP) molecules 131, 133, 173
death effector domains (DEDs) 121
death-inducing signaling complex (DISC) 121
delayed graft function (DGF) 283
dendritic cells (DCs) 26–31
  classification 27–28
  function 28–30
  graft-versus-host disease sensors 174–175
  immunosuppressive drug effects 30–31
  lymph nodes 12–14
  origin and differentiation 26
  Peyer’s patches 17
  phenotypes 27–28
  plasmacytoid (pDCs) 175
  tolerance induction 30
desensitization strategies 211–212
desoxyspergualin (DSG) 31
diabetes, post-transplant 225, 249–251
diacylglycerol (DAG) 109
DNA sequencing 273–276
donation after cardiac or circulatory determination of death (DCDD) 284–285
  kidney 218
  liver 226
donor organ availability 281
  donor age significance 285–286
  heart 232
  kidney 218–219
  liver 226
  lung 230
  marginal donor organs 283–284
see also donation after cardiac or circulatory determination of death (DCDD)
Index

donors after cardiac or circulatory death (DCD) 284–285

donor-specific antibodies (DSAs) 99, 146

suppression therapies 207–211, 208

donor-specific transfusion 154

dyslipidemia 251–252

eculizumab 149, 208, 210–211

electrospinning 307–308

embryonic stem cells (ESCs) 298–299

epratuzumab 211

Epstein Barr virus (EBV), post-transplant lymphoproliferative disease association 225, 246–247, 248

erthropoietin (EPO) 256

everolimus 110–111, 189, 199–200

adverse effects 199–200

efficacy 199

mechanism of action 199, 200

extracellular matrix (ECM) 294, 307–308

scaffolds 294–295, 294, 307–308

Extracorporeal Liver Assist Device 293

Fas-associated death domain (FADD) 121

fingolimod 191

Flice-inhibitory protein (c-FLIP) 121

follicular dendritic cells (FDCs) 12

Forkhead protein P3 (FoxP3) 39–40, 124–126, 152, 178

ganciclovir 241

gene therapy 309–314, 311

application to transplantation 312

cellular transplantation 312–313

solid organs 313–314

gene delivery approaches 309–310

nonviral vectors 312

viral vectors 310–311

glucocorticoids 30–31, 40

bone mineral disorder association 253–254

glucose metabolism effects 250–251

hypertension association 255

GlyCAM-1 14

graft rejection see rejection

graft-versus-host disease (GVHD) 164–165, 169–181

acute 164–165

staging and grading 166

chronic 165

genetic basis 169–171

HLA matching 169–170

minor histocompatibility antigens 170

immunobiology 171–181, 172

costimulatory pathways 175, 176

effectors and amplifiers 180–181

mediators 177–180

sensors 173–177, 174

triggers 171–173

model limitations 181

graft-versus-leukemia (GVL) effect 167

granulocyte colony-stimulating factor (G-CSF) 175

granzyme B 260

gut associated lymphoid tissue (GALT) 234

haptokinesis 14

Hassall’s corpuscles 7

heart

stem cell-based therapy 301

transplantation 232–233

ABO incompatible transplantation in pediatric patients 232

animal models 322–323, 323, 329

challenges 233

current status 232

HeartMateXVE 294

hematopoiesis 26, 27

hematopoietic stem cells (HSCs) 3, 5, 165–166, 300

sources of 167

transplantation 155, 164–165, 303

allogeneic 167, 168, 168

complications 168–169

conditioning regimen 167, 168–169

indications 165

principles 165–169

syngeneic 167

hematopoietic tissue islands 3, 4

HepatAssist 293

hepatitis C (HCV) infection 228–229

Herpes zoster infection 243

high endothelial venules (HIVs)

lymph nodes 11, 12

Peyer’s patches 17

high-mobility group box-1 133

HLAs see human leukocyte antigens (HLAs)

human Herpes virus 8 (HHV-8) 248

humanized mice 334–336

human leukocyte antigens (HLAs) 85–86

cellular responses to HLA alloantigens 90–92
class I molecules 90
class II molecules 90
crossmatch testing 94–95, 97
  virtual crossmatch 96–97, 99
cross-reacting groups (CREGs) 96
gene polymorphism 88
graft-versus-host disease relationship 169–170
haplotypes 88–89, 89
identical stem cell transplant 214
inheritance 88–89
nomenclature 94, 95
structure 90, 91
typing 92–94
  animal studies 334, 335
  reverse sequence-specific oligonucleotide (rSSO) probe hybridization 92–93, 93
  sequence-based typing (SBT) method 93, 94
  sequence-specific primer (SSP) method 93, 93
see also anti-HLA antibodies; major histocompatibility complex (MHC)
human papillomavirus (HPV) 248–249
humoral rejection see antibody-mediated rejection (ABMR)
hyperlipidemia 251–252
hyperparathyroidism 254
hypertension 255
hypophosphatemia 254
idiopathic pneumonia syndrome (IPS) 169
Illumina sequencer 275
imaging 308–309
immune privilege 159–160
immune response
  age-related changes 281–283, 282
  kinetics 119
immune system 1–3, 2
immunoreceptor tyrosine-based activation motifs (ITAMs) 32, 108
immunoregulation 151–153
immunosenescence 287–288
immunosuppression
  allogeneic hematopoietic cell transplantation 168
calcineurin inhibitor minimization 206–207
heart transplantation 232
infections and 238
kidney transplantation 220
liver transplantation 227
lung transplantation 230
protocols 205–207
  steroid minimization regimen 205–206
small bowel transplantation 234
immunosuppressive drugs 184–192
bone mineral disorder relationships 253–254
dendritic cell effects 30–31
dyslipidemia and 252
elderly patients 288–289, 289
late withdrawal 214–215
post-transplant malignancy relationship 247–248
protein/biologic drugs 187, 192, 193–194, 202–204
depleting antibodies 202–203, 202
nondepleting antibodies and fusion proteins 203–204
small-molecule drugs 187, 188–191, 192–202
classification 187
see also immunosuppression; specific drugs
indoleamine 2-3-dioxygenase (IDO) 160, 176
induced pluripotent stem cells (iPS) 300
infections, post-transplant 225, 238–243
  elderly recipients 287
hematopoietic cell transplantation 169
timeline 239
urinary tract infection 239
xenotransplantation 291
see also specific infections
inflammation
graft-versus-host disease 180–181
ischemia reperfusion injury 129–130
lymphoid neogenesis 21
regulation 63
see also cytokines
innate immunity 143, 144
ischemic reperfusion injury 131–136
IL-10 role 136–137
non-toll-like receptor role 135–136
toll-like receptor role 131–135
operational tolerance and 272
inosine monophosphate dehydrogenase (IMPDH) inhibition 192–195, 195
inside-out signaling 112
integrins 180
interferon γ (IFN-γ) 59–60, 179
graft-versus-host disease relationship 171
interleukins (IL)
- IL-1α 51
- IL-1β 51
- IL-2 54–55, 115–116
  - receptor blockers 147
- IL-6 51–52
- IL-7 55–56
- IL-9 56
- IL-10 62–64
  - graft-versus-host disease relationship 171
  - innate immune activation 136–137
- IL-12 57–58
- IL-15 56–57
- IL-17 60–61
- IL-18 53–54
- IL-22 173
- IL-23 58
- IL-27 58–59
- IL-37 54

intestinal stem cells (ISCs), role in graft-versus-host disease 172–173

intestinal transplantation, animal models 324, 325, 329–330

see also small bowel transplantation

intra-epithelial lymphocytes (IELs) 18

intravascular ultrasound (IVUS) 233

intravenous immunoglobulins (IVIG)
  - adverse effects 209
  - desensitization strategies 212
  - efficacy 209
  - mechanism of action 209

ischemia reperfusion injury (IRI) 128–129, 130, 141

animal model applications 330

gene therapy 313

innate immune activation 131–137

- IL-10 role 136–137
- non-toll-like receptor role 135–136
- toll-like receptor role 131–135, 132, 134, 135

liver 129–131, 130

mechanism of organ injury 129–131

T cell role 137–139, 139

islet and pancreas transplantation, animal models 325, 327–329


Janus kinase (JAK) family 116

- inhibition 200–201

see also JAK/STAT signaling pathway

JC virus 225

Jun N-terminal kinase (JNK)
  - activation 130–131

Kaposi’s sarcoma 244–245

kidney disease
  - in nonrenal organ transplant recipients 229, 234
  - stem cell-based therapy 302

Kidney Donor Profile Index (KDPI) 283, 284

kidney transplantation 218–225

  - accommodation 161
  - animal models 323–324, 324, 327, 328
  - antibody-mediated rejection 146, 224
  - artificial kidneys 292, 292
  - challenges 220–225
  - allograft fibrosis 223–224, 223
  - antibody-mediated injury 224
  - calcineurin inhibitor-induced nephrotoxicity 197–198, 225
  - immune monitoring 220–222
  - late graft failure 224–225
  - post-transplant infections 225, 239
  - post-transplant malignancy 225, 243–244, 246
  - primary disease recurrence 225
  - current status 218–220
  - donor pool 218–219

  see also donor organ availability

  - immunomodulation 160
  - maintenance therapy 230

  - outcomes 220, 221–222
  - paired kidney exchange 219, 219
  - rejection biomarkers 262, 264
  - simultaneous liver kidney (SLK) transplantation 230
  - tolerance induction 214–215, 222–223

  - biomarkers 269–273, 274

  - urinary biomarkers of rejection 148

  - killer cell immunoglobulin-like receptors (KIRs) 91–92

  - graft-versus-host disease relationship 170–171

Langerhans cells (LCs) 174

leflunomide 241

left ventricular assist devices (LVADs) 232, 294

leukopenia 256–257

liver
  - immune privilege 160
Index

ischemia reperfusion injury 129–135, 130, 132, 134, 135
stem cell-based therapy 302–303
tolerance induction 214–215
veno-occlusive disease (VOD) 169
liver support systems 293, 293
liver transplantation 226–230
animal models 325–326, 326
challenges 228–230
post-transplant malignancy 229
primary disease recurrence 228
current status 226–228
donor pool 226
see also donor organ availability
outcomes 221–222, 226–227
recipient age significance 287
simultaneous liver kidney (SLK) transplantation 230
L-selectin 14
lung
stem cell-based therapy 301–302
transplantation 230–231
animal models 324–325
challenges 231
current status 230
outcomes 221–222, 230
lymph nodes 10, 11–14
cell trafficking 13–14
function 123
structure 11–12, 12
lymphocyte depletional therapies 156–157
lymphocyte function associated antigen-1 (LFA-1) 111–112
lymphoid tissues 2
see also primary lymphoid tissues; secondary lymphoid tissues; tertiary lymphoid tissues
lymphotoxins 21
macrophages 33–35
activation 34
role in rejection 34–35
MAAdCAM-1 14, 17
major histocompatibility complex (MHC) 28–29, 85–86, 104
class I 28, 86, 90, 104–105
class II 28, 86–87, 87, 90, 104–105
Class III 87
genomic organization 86–88, 87
see also human leukocyte antigens (HLAs)
malignancy, post-transplant 243–249, 245
clinical characteristics 244–247
Kaposi’s sarcoma 244–245
non-melanoma skin cancer 244
post-transplantation lymphoproliferative disorders 245–247
renal cell carcinoma 247
epidemiology 244
kidney transplant 225, 243–244, 246
liver transplant 229
pathogenesis 247–249, 247
immunosuppression 247–248
viral infections 248, 248
mammalian target of rapamycin (mTOR) 110
inhibitors 199–200
marginal donor organs 283–284
mesenchymal stem cells (MSCs) 4, 299–300
metabolomics 276
metformin 251
methotrexate 167–168
methylprednisolone 201
MICA antigens 100
microarray analysis 264
micro-cytotoxicity test 96
microRNA-based biomarkers 265–266, 267
minor histocompatibility antigens (MiHAs) 170
"missing self" hypothesis 33
mixed chimerism 155
animal models 332
xenografts 291
model for end-stage liver disease (MELD) allocation system 226–227
molecular adsorbent recycling system (MARS) 293
molecular self-assembly 308
monocytes 33–34
mouse models see animal models
mRNA profiling 260, 261
rejection biomarkers 262–264, 263
tolerance biomarkers 269–273
mucosa-associated lymphoid tissues (MALTs) 10
muromonab-CD3 193
mycophenolate mofetil (MMF) 31
elderly patients 288
hematopoietic cell transplantation 168
liver transplantation 227
lung transplantation 230
mycophenolic acid (MPA) 31, 189, 192–196
  adverse effects 196
  efficacy 196
  mechanism of action 192–196
myeloid cells 4
nanotechnology 306–308, 307
  imaging 308–309
natural killer (NK) cells 31–33, 45, 91–92
  activation 31–32, 32
  development 4
  ischemic reperfusion injury 139–140
  “missing self” hypothesis 33
  role in rejection 33
  signaling 31–32, 32
natural killer T (NKT) cells 44–46, 45
  graft-versus-host disease and 177
  ischemic reperfusion injury 139–140
  transplant response and 45–46
necroptosis 121, 133, 286
nephrotoxicity, calcineurin inhibitors 197–198, 225
neutrophil esterase (NE) 134
neutrophil infiltration, gastrointestinal tract 173
new-onset diabetes after transplantation (NODAT) 249–251
next-generation sequencing 273–276
non-Hodgkin lymphoma 245–246
nuclear factor (NF)-κB pathway 107, 109
  ischemia reperfusion injury and 129–130
nuclear factor of activated T cells (NFAT) family 108–109
nucleotide-binding oligomerization domain-2 (NOD-2) 135, 172
  graft-versus-host relationship 171, 172
operational tolerance 214, 227–228
  B cell signatures 269–271
  innate immunity and 272
  liver transplant recipients 227–228
  pediatric patients 227–228
  T cell signatures 271–272
organ availability see donor organ availability
Organ Procurement and Transplantation Network (OPTN) 96
organ scaffolds 294–295, 294
pamidronate 254
pancreas transplantation, animal models 325, 327–329
pancreatic beta cell regeneration 303
Paneth cells 173
parvovirus infection 243
pathogen-associated molecular pattern (PAMP) molecules 131, 172, 286
pattern recognition receptors (PRRs) 286
perforin 260
peri-arteriolar lymphoid sheath (PALS) 15, 17
Peyer’s patches 17–18, 18
phosphatase and tensin (PTEN) 133
phosphatidylinositol 3’-hydroxyl kinase (PI3K)-mediated pathways 109–111, 110, 111
  ischemia and reperfusion injury 133
plasma cells 5
  generation 146, 146
plasmacytoid dendritic cells (pDCs) 175
plasmapheresis 212
plerixafor 6
porcine endogenous retroviruses (PERVs) 291
porcine models see animal models
post-transplant lymphoproliferative disease (PTLD) 225, 245–247, 248
prednisone 191, 201–202
  adverse effects 202
  elderly patients 288
  mechanism of action 201–202
primary lymphoid tissues 1–2, 2, 3–10
  bone marrow 3–7, 4
  thymus 7–10, 8
primate models see animal models
programmed cell death 119–122, 120
prope tolerance 158
protein tyrosine kinase (PTK) 108
proteomic biomarkers 266–268
pyelonephritis 239
rapamycin (sirolimus) 30, 40, 110–111, 157, 189, 199–200
  adverse effects 199–200
  efficacy 199
  elderly patients 289
  hematopoietic cell transplantation 168
  mechanism of action 199, 200
RAS/MAPK pathway 107, 109
receptor for advanced glycation end products (RAGE) 133–134
regeneration 297–298
regulatory T cells (Tregs) 14, 30, 39–40, 123–126
  development of 124
  graft-versus-host disease and 178–179
immune regulation 152–153, 152
mechanism of action 124, 125
role in tolerance 19, 124–126, 158–159
rejection 143–149
animal model applications 330–331
antibody-mediated see antibody-mediated rejection (ABMR)
B cell role 42–43, 43
biomarkers 148, 262–268
microRNA 265–266, 267
mRNA profiles 262–264, 263
proteomics 266–268
bone marrow role 6–7
clinical manifestations 144–147
acute cellular rejection 144–145, 145
antibody-mediated rejection 145–146, 145
chronic rejection 147
hyperacute rejection 144
key research areas 148–149
noninvasive tests for rejection 148
therapeutics 148–149
macrophage role 34–35
natural killer cell role 33
secondary lymphoid tissue role 18–19
T-cell mediated (TCMR) 144–145, 145, 184
pathogenesis 185
tertiary lymphoid tissue role 22
thymus role 10
timeline model 262
unsolved issues 147
xenografts 289–291
see also specific organ transplants
renal cell carcinoma 247
renal transplantation see kidney transplantation
reperfusion injury see ischemia reperfusion injury (IRI)
reverse sequence-specific oligonucleotide (rSSO) probe hybridization 92–93, 93
rituximab 148, 208, 209–210
adverse effects 210
efficacy 210
mechanism of action 210
pharmacokinetics 209–210
RNA sequencing 276
rodent models see animal models
rosuvastatin 252
R-spondin1 (R-Spo1) 172
secondary lymphoid tissues 2, 2, 10–19
lymph nodes 11–14, 12
Peyer’s patches 17–18, 18
role in rejection and tolerance 18–19
spleen 14–17, 16
sensitization assessment 98–99
desensitization strategies 211–212
sequence-based typing (SBT) 93, 94
sequence-specific primers (SSPs) 92
HLA typing 93, 93
severe combined immune deficiency (SCID) 167
sialic acid-binding immunoglobulin-like lectins (Siglecs) 173
signal transducer and activator of transcription (STAT) 116, 133
see also JAK/STAT signaling pathway
simultaneous liver kidney (SLK) transplantation 230
simvastatin 252
sirolimus see rapamycin
skin cancer 244
skin transplantation, animal models 321–322
small bowel transplantation 233–234
challenges 234
current status 233–234
sotrastaurin 190
sphingosine-1-phosphate (S1P) 10, 14
spleen 10, 14–17
cell trafficking 17
function 15–16
marginal zone 15–16, 41
structure 15, 16
statins 252
stem cells 295, 297–298, 299
clinical applications 300–303
brain 301
heart 301
kidney 302
liver 302–303
lung 301–302
concepts 298
embryonic stem cells (ESCs) 298–299
future challenges 303–304
induced pluripotent stem cells (iPS) 300
intestinal (ISCs) 172–173
mesenchymal stem cells (MSCs) 4, 299–300
sources 298–300, 299
very small embryonic-like stem cells (VSELs) 300
see also hematopoietic stem cells (HSCs)
steroid minimization regimen 205–206
late steroid discontinuation 205
steroid avoidance or rapid discontinuation 206
stop signal 112
streptavidin phycoerythrin (SAPE) 92
Strongyloides stercoralis 243
systems biology 276

TACI-Ig see atacicept
tacrolimus 30, 109, 157, 188, 197–199
adverse effects 197–198
drug interactions 198
efficacy 197
heart transplantation 232
hematopoietic cell transplantation 168
lung transplantation 230
mechanism of action 197, 198
T cell immunoglobulin mucin (TIM) family 43, 138
TIM-1–TIM-4 pathway 138–139, 139, 140
T cell-mediated rejection (TCMR) 144–145, 145, 184
pathogenesis 185
T cell receptor (TCR) 8–9, 104
signaling 105–109
T cells 26, 35–40, 103
activation 13, 21–22, 104–117, 106–107
amplification signals 109–111, 110, 111
costimulation 112–115, 114
cytokine signaling 115–117, 116
in transplantation 35–36
sequential signaling requirement 111–112, 112
age-related changes 283
antigen recognition 28, 29, 35
see also antigen presentation
CD8+ (cytotoxic) T cells 37–38, 37, 104–105
graft-versus-host disease and 177, 179
immune regulation 151–152
ischemic reperfusion injury 137–139, 139
subsets 38–39, 39, 117–118, 117, 179
Th1 (follicular helper T cells) 13, 14, 39, 118
Th2 38, 118
Th9 38
Th17 21, 38, 118
Th22 38
CD4+ (helper) T cells 38–39, 104–105
graft-versus-host disease and 177
cell trafficking into target organs 179–180
clonal deletion 149–150
deployment protocols 214
development 7, 8
differentiation to effector cells 117–118, 117
effector function 36–38
gamma-delta T cells 176
lymph nodes 12–14
memory T cells 40, 122–123, 156
central and effector memory T cells 123
graft-versus-host disease and 177–178
progression to 119–123
tolerance resistance 155–156
operational tolerance signatures 271–272
regulation of 39–40
selection 8–9
negative selection 149–150
spleen 15
tolerance mechanisms 149–150, 151
T suppressor cells 40
see also regulatory T cells (Tregs)
tertiary lymphoid tissues 3, 20–22
function 21–22
genesis 21
role in rejection and tolerance 22
structure 20–21, 20
thrombotic microangiopathy (TMA) 256
thymectomy effect 10
thymic epithelial cells (TECs) 7, 9
thymic stromal lymphopoeitin (TSLP) 7
thymus 7–10
cell trafficking 9–10
function 8–9
role in rejection and tolerance 10
structure 7, 8
tissue engineering 294–295
traptinibib 190, 200–201
adverse effects 201
efficacy 201
mechanism of action 200–201
tolerance 143, 149–159, 268
animal models 331–333
apoptosis role 122
biomarkers 159, 268–273, 274
B cell signatures 269–271
T cell signatures 271–272
bone marrow role 6–7
central tolerance mechanisms 149–150
classification 268
dendritic cell role 30
induction strategies 151–155, 186, 214–215
costimulation blockade 153–154
donor-specific transfusion 154
gene therapy 312–313
immune regulation 151–153
mixed chimerism 155, 291, 332
xenografts 291
key research areas 158–159
biomarkers 159
regulatory T cells 158–159
operational tolerance 214, 227–228, 269–272
innate immunity and 272–273
pediatric patients 227–228
peripheral tolerance mechanisms 150–151, 150
prope tolerance 158
resistance mechanisms 155–157
homeostatic repopulation 156–157
memory T cells 155–156
non-tolerogenic
immunosuppression 157
secondary lymphoid tissue role 18–19
tertiary lymphoid tissue role 22
thymus role 10
unresolved issues 157–158
toll-like receptors (TLRs) 29, 286
ischemia reperfusion injury role 131–135, 132, 134, 135
transforming growth factor β (TGF-β) 61–62
transplant-associated hyperglycemia (TAH) 249–251, 250
risk factors 251
transplant rejection see rejection
transplant-related complications 237–238
causes of death with a functioning allograft 238, 238
donor age relationships 285–286
hematologic disorders 255–257
hypertension 255
infections 225, 238–243, 259, 287
malignancy 243–249
clinical characteristics 244–247
epidemiology 244
pathogenesis 247–249
metabolic disorders 249–255
bone mineral disorder 253–255, 253
dyslipidemia 251–252
transplant-associated hyperglycemia (TAH) 249–251, 250, 251
recipient age relationships 286–288
see also specific complications; specific organ
transplants
transplant tolerance see tolerance
transplant vasculopathy 99
Tregs see regulatory T cells (Tregs)
tumor necrosis factor α (TNFα) 52–53
graft-versus-host disease relationships 171
role in ischemia reperfusion injury 129–131
urinary biomarkers of rejection 148
urinary tract infection 239
valganciclovir 241, 256
vascularized composite allotransplantation (VCA) 304–306
challenges 305–306
complications 306
current research 306
procedures 305
ventricular assist devices (VADs) 232, 294
very small embryonic-like stem cells (VSELs) 300
viral infections 29–30
virtual crossmatch 96–97, 99
VLA-4 integrin 6
voclosporin 188, 197
vorinostat 178
Weibel–Palade bodies 50
WHIM syndrome 6
xenotransplantation 289–291
immunological issues 289–291
infection risk 291
XM-One assay 100
ZAP-70 108